The following was reported to gore: on (b)(6) 2022, a patient presented with an occluded left superficial femoral artery (sfa) and underwent treatment utilizing a gore® viabahn® endoprosthesis with heparin bioactive surface.Access for the procedure was from the common femoral artery down to the proximal popliteal artery and the physician proceeded to access through the anterior tibial artery with a 7 fr sheath.The viabahn device was loaded onto an 0.018 guidewire, but could not advance while in the tibial peroneal trunk.The physician decided to remove the viabahn device, but it was found to be stuck in the sheath.During removal attempts, the tip of the catheter partially separated but did not completely detach from the delivery system.The deployment line also broke during removal attempts.There was no reported device deployment.The physician switched to an 8 fr sheath and removed the viabahn device and delivery system by re-sheathing and pulling the device out of the patient.The procedure was completed with two alternate viabahn devices.
|
Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|